AG1 vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Single-SKU greens supplement brand projecting $600M revenue in 2025 at $1.2B valuation; built almost entirely on DTC subscriptions with no retail distribution; endorsed by Andrew Huberman and powered by word-of-mouth among health-conscious consumers.
About
AG1 (formerly Athletic Greens) is a New Zealand-founded, US-focused nutritional supplement company that manufactures a single flagship product: a daily all-in-one greens powder. Founded in 2010 and now headquartered in Las Vegas, the company bootstrapped to approximately $160 million in revenue before raising $115 million in a growth round in January 2022 at a $1.2 billion valuation, led by Alpha Wave Global.\n\nAG1 projects revenue of approximately $600 million in 2025, driven almost entirely by direct-to-consumer subscriptions sold online. The company has no retail distribution and no SKU diversification — an unusual strategy that has proven powerful for brand clarity and margin preservation. AG1 products are endorsed by high-profile athletes and health podcasters including Andrew Huberman, fueling viral word-of-mouth and podcast advertising at scale.\n\nIn 2025 the company began expanding into complementary product lines while retaining its minimalist brand identity. Its subscription model creates strong LTV economics, and the company has been reportedly cash-flow positive since well before its funding round. AG1 is often cited as a benchmark for DTC supplement brand building.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.